Waiting for the next wave...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@barttrab11 - invited to Vegas
You are welcome
Now I understand why they have the largest population in the world !!!
The best to end the week lol...
But they do not know who are their companions... Laws of evolution... 🐐
Friday volume - 1 mil by 1 PM...
I'll drink to that !!!
A schyzo cult!!!
GME !!!
---------------
Too late to cover. The losses are massive. 2.8 cents to 20 cents? lol dude that's probably an 8 figure loss if I've made 7 figures riding it up.
she is waking up
19 days to the best show in town
You tell me - what orders did you get today?
-----------
So, another red day?
Again pre-market action
Drama 👑 has another episode lol
Talking to himself now !!! lol
---------------
Good call. You were right.
For me it could mean very early retirement
Chief borrower officer
Passed 1 Mil at 10:43 AM
Dollar land should be 227 Million in sales...
This chat GPT reply shows us that if we make 60 Million in revenue this year we should be at 26.4 cents. just based on sales. without even counting the pipeline growth...
The P/E ratio, or price-to-earnings ratio, is a measure of how expensive a company’s stock is relative to its earnings. A high P/E ratio indicates that investors are willing to pay more for a company’s future growth potential, while a low P/E ratio suggests that the company is undervalued or has low growth prospects.
According to one source1, the average P/E ratio for the pharmaceutical industry as of January 19, 2024 was 35.8, which is higher than its 3-year average of 41.6. However, this figure may vary depending on the specific segment and criteria of the industry.
For example, another source2 reported that the P/E ratio for the U.S. pharma industry was 52.6 as of May 8, 2020, which is higher than the global average of 38.9. This source also noted that the industry is trading close to its 3-year average PS ratio of 4.4, which is another valuation metric based on sales rather than earnings.
To find the P/E ratio of pharmaceutical companies manufacturing generics with no debt, profitable for 5 years and growing steadily with a bright forecast for the next 2 years, one would need to narrow down the list of companies that meet these criteria and compare their stock prices and earnings per share.
One way to do this is to use a stock screener tool, such as the one available on [Yahoo Finance], which allows users to filter companies by various factors, such as industry, market cap, debt, profitability, growth, and outlook. Alternatively, one could also use a financial database, such as [Bloomberg] or [FactSet], to access more detailed and updated information on individual companies and their financial performance.
However, it is important to note that the P/E ratio is not the only indicator of a company’s value or potential. Other factors, such as the competitive landscape, the regulatory environment, the innovation pipeline, the customer demand, and the macroeconomic trends, should also be considered when evaluating a company’s prospects and attractiveness. Therefore, the P/E ratio should be used in conjunction with other tools and metrics, such as the PEG ratio, the ROE, the EPS growth, the dividend yield, and the DCF analysis, to get a more comprehensive and balanced view of a company’s worth.
Schwab Phone app is not good - you need to refresh all the time - I miss my good old TD app !!!
Schwab shows screwed up view - losing money on my total but up 7% lol
Pre-market trading again - bid this time
The P/E ratio, or price-to-earnings ratio, is a measure of how expensive a company’s stock is relative to its earnings. A high P/E ratio indicates that investors are willing to pay more for a company’s future growth potential, while a low P/E ratio suggests that the company is undervalued or has low growth prospects.
According to one source1, the average P/E ratio for the pharmaceutical industry as of January 19, 2024 was 35.8, which is higher than its 3-year average of 41.6. However, this figure may vary depending on the specific segment and criteria of the industry.
For example, another source2 reported that the P/E ratio for the U.S. pharma industry was 52.6 as of May 8, 2020, which is higher than the global average of 38.9. This source also noted that the industry is trading close to its 3-year average PS ratio of 4.4, which is another valuation metric based on sales rather than earnings.
To find the P/E ratio of pharmaceutical companies manufacturing generics with no debt, profitable for 5 years and growing steadily with a bright forecast for the next 2 years, one would need to narrow down the list of companies that meet these criteria and compare their stock prices and earnings per share.
One way to do this is to use a stock screener tool, such as the one available on [Yahoo Finance], which allows users to filter companies by various factors, such as industry, market cap, debt, profitability, growth, and outlook. Alternatively, one could also use a financial database, such as [Bloomberg] or [FactSet], to access more detailed and updated information on individual companies and their financial performance.
However, it is important to note that the P/E ratio is not the only indicator of a company’s value or potential. Other factors, such as the competitive landscape, the regulatory environment, the innovation pipeline, the customer demand, and the macroeconomic trends, should also be considered when evaluating a company’s prospects and attractiveness. Therefore, the P/E ratio should be used in conjunction with other tools and metrics, such as the PEG ratio, the ROE, the EPS growth, the dividend yield, and the DCF analysis, to get a more comprehensive and balanced view of a company’s worth.
Drama 🤴
Drama king!!! 👑🤴
Watching dumb money on Netflix. Movie about GameStop.
We are at the same stage as GameStop after first 6 months. 5 baggers from summer to January.
Just saying.
The fat lady still needs to sing
OMG LOL I forgot of the laws of Physics hahaha
Not stupidity for sure lol
Hey Doc, nice try - I was there with the previous CEO etc... but your CGC is bleeding money losing $15 per share lol. Not for me - pass... I will stick to what we know. ELTP BABY
Your trick about going red blew up to your face. 🐐
The CBO - chief borrowing officer- namtae!!!
about two million shares again in next 5 minutes. Way to go !!!
It would be interesting to see you pant less...
You should seriously consider changing job AMA.
How much is 80K in Rupees?
Our Mascot is a goat 🐐
And I would add: HE DOES NOT OWN ONE SHARE. HE HAS PLENTY OF BORROWED SHARES.
This is the reason why I give you 👺 -
You are not stable - as soon as we have a little dip you come up with a story instead of waiting for it to come back up...
Coming over
Welcome to the new longs
I see many new names here - welcome to the 2024 Millionaire run...
DUH!!!
Namtae decided to buy pre-market? LOL